Lecanemab Injection Market Report 2026

The lecanemab injection market size has grown exponentially in recent years. It will grow from $2.53 billion in 2025 to $3.07 billion in 2026 at a compound annual growth rate (CAGR) of 21.5%. The growth in the historic period can be attributed to accelerated fda approval, phase 3 clarity and trial success, demonstration of amyloid plaque reduction, full medicare reimbursement coverage and abandonment of prior amyloid therapies.

The lecanemab injection market size is expected to see exponential growth in the next few years. It will grow to $6.63 billion in 2030 at a compound annual growth rate (CAGR) of 21.2%. The growth in the forecast period can be attributed to increasing early-stage diagnosis rates, growing acceptance by specialty physicians, rising global aging population, expansion of reimbursement in European markets and increasing patient adherence due to sc formulation. Major trends in the forecast period include technological advancements in blood-based biomarkers, innovations in subcutaneous injection devices, research and development into pre-clinical treatment, developments in simplified monthly dosing and technological advancements in remote patient monitoring.

The rising prevalence of Alzheimer’s disease is expected to drive the growth of the lecanemab injection market in the coming years. Alzheimer’s disease prevalence refers to the number of individuals living with a clinical diagnosis of Alzheimer’s dementia within a given population. The increase in Alzheimer’s disease prevalence is largely attributed to an aging population, as advancing age is the most significant risk factor for developing the condition. Lecanemab injection supports the management of Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which play a central role in disease progression. It helps improve patient outcomes by slowing cognitive decline and enhancing the quality of life for people living with Alzheimer’s. For example, in April 2025, according to the Alzheimer’s Association, a US-based nonprofit health organization, approximately 7.2 million Americans aged 65 and older were living with Alzheimer’s dementia, with nearly 74% aged 75 or above. By 2030, the entire baby boomer generation (born between 1946 and 1964) will have reached 65 years of age or older, substantially expanding the population at highest risk for Alzheimer’s dementia. As a result, the increasing prevalence of Alzheimer’s disease is contributing to the growth of the lecanemab injection market.

Major participants in the lecanemab injection market are concentrating on the development of advanced therapeutic solutions, including humanized immunoglobulin gamma 1 (IgG1) monoclonal antibodies, to provide treatments that extend beyond symptom relief and slow the progression of cognitive decline. A humanized IgG1 monoclonal antibody is a laboratory-engineered antibody in which variable regions derived from a non-human source are grafted onto a predominantly human IgG1 framework, allowing targeted antigen binding while minimizing immune rejection. For example, in August 2025, Eisai Co. Ltd., a Japan-based, innovation-driven healthcare company, introduced Leqembi (lecanemab) in the European Union. This therapy became the first treatment approved by the European Commission to address an underlying cause of Alzheimer’s disease. It features a dual mechanism that targets both amyloid plaques and protofibrils, potentially influencing downstream tau accumulation and enabling a direct intervention in the biological processes of the disease.

In November 2024, Eisai Co. Ltd., a Japan-based innovation-driven healthcare company, entered into a partnership with the National Center of Neurology and Psychiatry (NCNP) to initiate apolipoprotein E (APOE) genetic testing in support of anti-amyloid beta antibody therapies such as lecanemab injection (LEQEMBI). Through this collaboration, Eisai and NCNP aim to examine the relationship between APOE genotype and the safety and effectiveness of lecanemab treatment, leverage APOE genetic information alongside post-marketing surveillance data, and support regulatory re-examination activities by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to optimize patient outcomes. The National Center of Neurology and Psychiatry (NCNP) is a Japan-based national research institution.

Major companies operating in the lecanemab injection market are Biogen Inc., Eisai Co. Ltd.

North America was the largest region in the lecanemab injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lecanemab injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lecanemab injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the lecanemab injection market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing equipment, cold-chain packaging materials, and infusion-related medical supplies. healthcare providers and pharmaceutical manufacturers in north america and europe are most affected due to dependence on cross-border biologics supply chains, while asia-pacific faces pricing pressure on formulation and distribution. these tariffs are contributing to higher treatment costs and reimbursement challenges. however, they are also encouraging localized biologics manufacturing, regional supply diversification, and investments in domestic pharmaceutical production infrastructure.

Lecanemab injection is a monoclonal antibody treatment developed to target and eliminate amyloid-beta plaques in the brain. Its main purpose is to slow cognitive decline in individuals with early-stage Alzheimer’s disease by reducing the accumulation of these harmful proteins. The therapy is administered intravenously under medical supervision as part of Alzheimer’s disease management.

The primary types of lecanemab injection include 200 mg and 500 mg vial presentations. The 200 mg vial is formulated for precise dosing in treating Alzheimer’s disease during early and mild stages. Administration formats include intravenous infusion and subcutaneous injection. Patient categories include early Alzheimer’s, mild cognitive impairment, and moderate disease, across age groups 60-70, 71-80, and 81+. Distribution occurs through hospital, online, and retail pharmacies.

The lecanemab injection market consists of sales of lecanemab monoclonal antibody injection vials, intravenous infusion formulations, prefilled injection formats, companion diagnostic products for amyloid detection, and supportive administration supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.